Journal
ALZHEIMERS & DEMENTIA
Volume 10, Issue 4, Pages 456-467Publisher
WILEY
DOI: 10.1016/j.jalz.2013.05.1774
Keywords
MRI; Image analysis; Memory clinics; Naturalistic population; Alzheimer's disease; Medial temporal lobe; Hippocampus
Categories
Funding
- Istituto Nazionale di Fisica Nucleare (INFN), Italy
- Universita degli Studi di Genova, Italy
- EADC
- European Commission (DESCRIPA) [QLK-6-CT-2002-02455]
- ADNI (National Institutes of Health) [U01 AG024904]
- NIA
- NIBIB
- Abbott
- AA
- Alzheimer's Drug Discovery Foundation
- Amorfix Life Sciences, Ltd.
- AstraZeneca
- Bayer HealthCare
- BioClinica, Inc.
- Biogen Idec, Inc.
- Bristol-Myers Squibb Company
- Eisai, Inc.
- Elan Pharmaceuticals, Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche, Ltd.
- Genentech, Inc.
- GE Healthcare
- Innogenetics, N.V.
- IXICO, Ltd.
- Janssen Alzheimer Immunotherapy Research & Development, LLC.
- Johnson & Johnson Pharmaceutical Research & Development, LLC.
- Medpace, Inc.
- Merck Co., Inc.
- Meso Scale Diagnostics, LLC.
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc.
- Servier
- Synarc, Inc.
- Takeda Pharmaceutical Company
- Canadian Institutes of Health Research
- NIH [P30 AG010129, K01 AG030514]
Ask authors/readers for more resources
Background: In the framework of the clinical validation of research tools, this investigation presents a validation study of an automatic medial temporal lobe atrophy measure that is applied to a naturalistic population sampled from memory clinic patients across Europe. Methods: The procedure was developed on 1.5-T magnetic resonance images from the Alzheimer's Disease Neuroimaging Initiative database, and it was validated on an independent data set coming from the DESCRIPA study. All images underwent an automatic processing procedure to assess tissue atrophy that was targeted at the hippocampal region. For each subject, the procedure returns a classification index. Once provided with the clinical assessment at baseline and follow-up, subjects were grouped into cohorts to assess classification performance. Each cohort was divided into converters (co) and nonconverters (nc) depending on the clinical outcome at follow-up visit. Results: We found the area under the receiver operating characteristic curve (AUC) was 0.81 for all co versus nc subjects, and AUC was 0.90 for subjective memory complaint (SMCnc) versus all co subjects. Furthermore, when training on mild cognitive impairment (MCI-nc/MCI-co), the classification performance generally exceeds that found when training on controls versus Alzheimer's disease (CTRL/AD). Conclusions: Automatic magnetic resonance imaging analysis may assist clinical classification of subjects in a memory clinic setting even when images are not specifically acquired for automatic analysis. (C) 2014 The Alzheimer's Association. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available